In December 1996, Sandoz and Ciba-Geigy merged to form Novartis in one of the largest corporate mergers in history. Sandoz remained as a subsidiary of Novartis and today develops, manufactures and ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

"At Novartis, we have a long history of being at the forefront of transformative cancer treatment," said Joseph Jimenez, CEO of Novartis. "Five years ago, we began collaborating with the ...

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...

Novartis AG's ( VTX:NOVN ) dividend will be increasing from last year's payment of the same period to $3.50 on 13th ...

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...

Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative ...

Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 ...

Shares of Swiss pharmaceutical giant Novartis AG were flat on Friday morning in heavy trading volume, despite the company reporting impressive quarterly results. Novartis posted core fourth-quarter ...

Novartis is airing its first-ever Super Bowl ad to raise awareness about breast cancer and promote regular screenings. The ...